Medtronic (MDT) affirmed its shareholder return policy on 20 August 2026, as the board approved a second quarter fiscal 2027 cash dividend of $0.72 per ordinary share, payable on 16 October 2026.

Medtronic’s latest dividend affirmation comes after a period of stronger short term share price momentum, with a 90 day share price return of 20.3% and a 30 day gain of 12.19%. Over the same time frame, the 1 year total shareholder return of 4.72% and 3 year total shareholder return of 26.58% sit against a year to date share price decline of 2.81% and a current share price of $93.35.

If this kind of recovery story interests you, it could be a good moment to see what else is moving in healthcare AI and review the 41 healthcare AI stocks

Medtronic’s recent rebound, set against a weaker year to date share price and mixed multi year returns, raises a simple issue: Are investors now paying more for clear business progress or for a change in sentiment around the stock? The valuation section tackles this next.

Most Popular Narrative: 3.3% Overvalued

Medtronic’s last close at $93.35 sits modestly above the narrative fair value of $90.37, which frames the stock as slightly expensive on this view.

Diversification in my portfolio meant investing in the healthcare sector. I already owned Pfizer. Functional and technical analysis showed Medtronic plc to be a good addition for the longer term. Actual indicators for this moment: P/E fwd ~13.5, PEG ~1.6, Debt/Equity ~57%, EPS ~11%, Payout ~76%, and Operational Cash Flow approx. $7.3 billion. MACD above signal line, RSI 54.26, MOM and OBV positive. Medtronic plc recently acquired Scientia Vascular to expand its neurovascular technology portfolio. Although analysts are showing some caution and issuing various price targets, I found the timing of entry favorable. My investment horizon is 5 to 10 years. Medtronic plc is not spectacular in its growth but does grow over the long term. Medtronic plc is a dividend aristocrat. The number of years of dividend growth is 50 years. I cautiously bought a small group of 5 shares to monitor it more closely and potentially invest further. The healthcare weighting in my portfolio is now 2%.

Curious what sits behind that $90.37 fair value for Medtronic and a small 3.3% premium? To understand it, follow how earnings, margins and future valuation multiples tie together in this narrative.

Result: Fair Value of $90.37 (OVERVALUED)

However, you also need to keep an eye on execution risks in Medtronic’s large device portfolio, as well as any shifts in healthcare spending that could pressure margins.

Another View on Medtronic’s Valuation

The user narrative frames Medtronic as 3.3% overvalued at $93.35 versus a $90.37 fair value. A different perspective comes from earnings multiples. Medtronic trades on a 24.9x P/E, which is lower than the industry average of 27.4x and below a fair ratio of 30.7x, which highlights a valuation gap that some investors may consider significant.

Next Steps

With mixed signals across Medtronic’s valuation views and returns, it helps to check the underlying data yourself and move quickly while sentiment is still forming. To see what investors are optimistic about right now, review the 5 key rewards

Looking For More Investment Ideas Beyond Medtronic?

Medtronic is just one part of the picture. If you want a fuller opportunity set, now is a time to scan other stocks before sentiment moves on.

• Spot potential income anchors for your portfolio by checking out 12 dividend fortresses that may offer more dependable cash generation alongside capital exposure.
• Hunt for quality at a price that still looks reasonable by reviewing the 48 high quality undervalued stocks and see which stocks currently screen as attractively priced.
• Strengthen your downside protection by focusing on resilience through the 75 resilient stocks with low risk scores and avoid missing stocks that may hold up better when conditions get tougher.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.